Loading...
Market
Will results from Phase 1 clinical trials for anti-IL-11 therapies be published in a peer-reviewed journal by December 31, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Peer-reviewed journals and announcements from research institutions or pharmaceutical companies
Story
Nature Study: Inhibiting IL-11 Protein Extends Lifespan of Mice by 25%, Clinical Trials Underway
Jul 17, 2024, 04:51 PM
A recent study published in Nature reveals that inhibiting the pro-inflammatory protein interleukin-11 (IL-11) can extend the lifespan of mice by up to 25%. The research demonstrated that both genetic deletion and pharmacological inhibition of IL-11 significantly increased the median lifespan of male mice by 22.5% and female mice by 25%. The treated mice, referred to as 'supermodel grannies' due to their youthful appearance, also exhibited improved health, strength, and reduced age-related health problems. Preclinical studies support the evaluation of IL-11 inhibition on aging pathologies in older people. Anti-IL-11 therapies are already in early clinical trials for human applications, raising hopes that similar anti-aging effects could be achieved in humans. Additionally, the treatment has been shown to reduce the incidence of cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Nature • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
